Literature DB >> 22693935

[Chronic rheumatic manifestations following chikungunya virus infection: clinical description and therapeutic considerations].

A Ribéra1, I Degasne, M C Jaffar Bandjee, Ph Gasque.   

Abstract

The chikungunya virus epidemic that occurred on Reunion Island from May 2005 to the end of 2006 affected 30% of the population (more than 250 000 people). As a result of its major clinical impact, this outbreak allowed better documentation of the acute phase of the disease. The disease generally has a slowly self-limiting course over a period of several months with rheumatic manifestations. For practitioners, these symptoms raise numerous questions at several levels, i.e., i) role of the virus in pain, ii) most appropriate treatment, and iii) prevention of development of chronic symptoms. This study in two patient cohorts on Reunion Island was carried out in an attempt to improve understanding and management of chronic rheumatic manifestations following chikungunya virus infection. Findings in 360 patients presenting painful manifestations following chikungunya virus infection showed that the risk of developing inflammatory polyarthritis was higher if the initial acute phase lasted longer than 3 weeks. Based on this observation, it is recommended that these patients undergo rheumatologic evaluation at 3 months to assess the need for possible immunosuppressor treatment (methotrexate).

Entities:  

Mesh:

Year:  2012        PMID: 22693935

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  9 in total

1.  How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

Authors:  A J Rodriguez-Morales; J A Cardona-Ospina; W Villamil-Gómez; A E Paniz-Mondolfi
Journal:  Rheumatol Int       Date:  2015-06-05       Impact factor: 2.631

Review 2.  Chikungunya Infection: a Global Public Health Menace.

Authors:  A J Mathew; A Ganapati; J Kabeerdoss; A Nair; N Gupta; P Chebbi; S K Mandal; Debashish Danda
Journal:  Curr Allergy Asthma Rep       Date:  2017-02       Impact factor: 4.806

3.  Post-Chikungunya rheumatoid arthritis, Saint Martin.

Authors:  Maud Foissac; Emilie Javelle; Simon Ray; Bruno Guérin; Fabrice Simon
Journal:  Emerg Infect Dis       Date:  2015-03       Impact factor: 6.883

4.  Chikungunya and the eye: a review.

Authors:  Padmamalini Mahendradas; Kavitha Avadhani; Rohit Shetty
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-02-11

5.  Specific management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in Reunion Island from 2006-2012.

Authors:  Emilie Javelle; Anne Ribera; Isabelle Degasne; Bernard-Alex Gaüzère; Catherine Marimoutou; Fabrice Simon
Journal:  PLoS Negl Trop Dis       Date:  2015-03-11

6.  Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island.

Authors:  Jean-Jacques Hoarau; Frederick Gay; Olivier Pellé; Assia Samri; Marie-Christine Jaffar-Bandjee; Philippe Gasque; Brigitte Autran
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

7.  Identification of initial severity determinants to predict arthritis after chikungunya infection in a cohort of French gendarmes.

Authors:  Hafiz Muhammad Yaseen; Fabrice Simon; Xavier Deparis; Catherine Marimoutou
Journal:  BMC Musculoskelet Disord       Date:  2014-07-24       Impact factor: 2.362

Review 8.  Chikungunya vaccines in development.

Authors:  Michael Schwameis; Nina Buchtele; Patricia Pia Wadowski; Christian Schoergenhofer; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 9.  Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy.

Authors:  Simon-Djamel Thiberville; Nanikaly Moyen; Laurence Dupuis-Maguiraga; Antoine Nougairede; Ernest A Gould; Pierre Roques; Xavier de Lamballerie
Journal:  Antiviral Res       Date:  2013-06-28       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.